Abstract
Case
A case study of a patient who over complied with adjuvant capecitabine monotherapy on several occasions is described. The patient suffered worsening side effects, predominantly palmar plantar erythrodysesthesia which resulted in dose reduction and delay. The patient had disregarded advice to stop taking the capecitabine as he perceived it as “important to fight his cancer”. The patient refused review with a psychologist.
Conclusion
There is a lack of evidence regarding the issue of over compliance. Pharmacists should consider discussing patient’s attitudes towards taking their medication and its importance to them in treating their cancer. Tools that are used to assess non-compliance could be utilised to identify patients who over comply. Further research is required to gain further understanding of the psychological factors behind patient’s decisions to over comply with treatment.
References
Simchowitz B, Shiman L, Spencer J, Brouillard D, Gross A, Connor M, et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs. 2010;14(4):447–53.
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.
Winkeljohn D. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2010;14(4):461–6.
Partridge AH, Wang PS, Winer PS, Avorn J, Weingart SN. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.
Timmers L, Boons C, Mangnus D, Moes J, Swart E, Boven E, et al. The use of erlotinib in daily practice: a study on adherence and patients’ experiences. BMC Cancer. 2011;11:284.
Nilsson J, Andersson K, Bergkvist A, Björkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care. 2006;15(3):235–7.
Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–8.
Oncology Nursing Society. adherence to oral therapies for cancer: helping your patient stay on course toolkit. http://www.ons.org/ClinicalResources/OralTherapies/Toolkit. Accessed 5th December 2013.
Timmers L, Swart E, Boons C, Mangnus D, van de Ven PM, Godefridus P, et al. The use of capecitabine in daily practice: a study on adherence and patients’ experiences. Patient Prefer Adher. 2012;6:741–8.
Funding
None.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Allen, J., Williamson, S. Over compliance with capecitabine oral chemotherapy. Int J Clin Pharm 36, 271–273 (2014). https://doi.org/10.1007/s11096-014-9921-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-014-9921-1